<?xml version="1.0" encoding="iso-8859-1"?>
<frameset>
<predicate lemma="recognize">
<roleset id="recognize.01" name="" wordnet="3">
<roles>
  <role n="0" descr="agent
"/>
  <role n="1" descr="thing being identified
"/>
</roles>
<example src="MEDLINE" no="1">
<text>
As a result of alternate splicing and subsequent frameshift, the reported g16 protein is 603 amino acids shorter than the NY-LU-12 product (1123 residues) at its COOH terminus and would therefore lack the epitopes recognized by the autologous serum.

</text>
       <arg n="0">the autologous serum
</arg>
       <arg n="1">the epitopes
</arg>
<fdg>
1	As	as	cla:&gt;15	@ADVL %EH PREP
2	a	a	det:&gt;3	@DN&gt; %&gt;N DET SG
3	result	result	pcomp:&gt;1	@&lt;P %NH N NOM SG
4	of	of	mod:&gt;3	@&lt;NOM-OF %N&lt; PREP
5	alternate	alternate	attr:&gt;6	@A&gt; %&gt;N A ABS
6	splicing	splicing	cc:&gt;8	@A&gt; %&gt;N A ABS
7	and	and	cc:&gt;8	@CC %CC CC
8	subsequent	subsequent	attr:&gt;9	@A&gt; %&gt;N A ABS
9	frameshift	frameshift	pcomp:&gt;4	@&lt;P %NH &lt;?&gt; N NOM SG
10	,	,
11	the	the	det:&gt;14	@DN&gt; %&gt;N DET
12	reported	reported	attr:&gt;13	@A&gt; %&gt;N A ABS
13	g16	g16	attr:&gt;14	@A&gt; %&gt;N N NOM SG
14	protein	protein	subj:&gt;15	@SUBJ %NH N NOM SG
15	is	be	main:&gt;0	@+FMAINV %VA V PRES SG3
16	603	603	qn:&gt;18	@QN&gt; %&gt;N NUM CARD
17	amino	amino	attr:&gt;18	@A&gt; %&gt;N N NOM SG
18	acids	acid	comp:&gt;15	@PCOMPL-S %NH N NOM PL
19	shorter	short	mod:&gt;18	@&lt;NOM %N&lt; A CMP
20	than	than	mod:&gt;19	@ADVL %EH PREP
21	the	the	det:&gt;23	@DN&gt; %&gt;N DET
22	NY-LU-12	ny-lu-12	attr:&gt;23	@A&gt; %&gt;N N NOM SG
23	product	product	pcomp:&gt;20	@&lt;P %NH N NOM SG
24	(	(
25	1123	1123	qn:&gt;26	@QN&gt; %&gt;N NUM CARD
26	residues	residue	mod:&gt;23	@APP %NH N NOM PL
27	)	)
28	at	at		@ADVL %EH PREP
29	its	it	attr:&gt;30	@A&gt; %&gt;N PRON GEN SG3
30	COOH	cooh	attr:&gt;31	@A&gt; %&gt;N N NOM SG
31	terminus	terminus	pcomp:&gt;28	@&lt;P %NH N NOM SG
32	and	and	cc:&gt;15	@CC %CC CC
33	would	would	v-ch:&gt;35	@+FAUXV %AUX V AUXMOD
34	therefore	therefore	meta:&gt;35	@ADVL %EH ADV
35	lack	lack	cc:&gt;15	@-FMAINV %VA V INF
36	the	the	det:&gt;37	@DN&gt; %&gt;N DET
37	epitopes	epitop*	obj:&gt;35	@OBJ %NH &lt;?&gt; N NOM
38	recognized	recognize	mod:&gt;37	@-FMAINV %VP EN
39	by	by	ha:&gt;38	@ADVL %EH PREP
40	the	the	det:&gt;42	@DN&gt; %&gt;N DET
41	autologous	autologous	attr:&gt;42	@A&gt; %&gt;N A ABS
42	serum	serum	pcomp:&gt;39	@&lt;P %NH N NOM SG
43	.     .
</fdg>
</example>
<example src="MEDLINE" no="2">
<text>
These mutations, identified by standard methods of reverse transcription, PCR,dideoxy-chain termination, and cycle sequencing, alter highly conserved sequences at intron/exon boundaries and prevent the RNA-splicing apparatus from properly recognizing the normal splice junction.

</text>
       <arg n="0">the RNA-splicing apparatus
</arg>
       <arg n="1">the normal splice junction
</arg>
<fdg>

1	These	this	det:&gt;2	@DN&gt; %&gt;N DET DEM PL
2	mutations	mutation		@NH %NH N NOM PL	@SUBJ %NH N NOM PL	@OBJ %NH N NOM PL
3	,	,
4	identified	identify	mod:&gt;2	@-FMAINV %VP EN
5	by	by	ha:&gt;4	@ADVL %EH PREP
6	standard	standard	attr:&gt;7	@A&gt; %&gt;N A ABS
7	methods	method	pcomp:&gt;5	@&lt;P %NH N NOM PL
8	of	of	mod:&gt;7	@&lt;NOM-OF %N&lt; PREP
9	reverse	reverse	attr:&gt;10	@A&gt; %&gt;N A ABS
10	transcription	transcription	pcomp:&gt;8	@&lt;P %NH N NOM SG
11	,	,
12	PCR	pcr	mod:&gt;10	@APP %NH ABBR NOM SG
13	,	,
14	dideoxy-chain	dideoxy-chain	attr:&gt;15	@A&gt; %&gt;N &lt;?&gt; N NOM SG
15	termination	termination		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG	@APP %NH N 

NOM SG	@A&gt; %&gt;N N NOM SG	@&lt;P %NH N NOM SG
16	,	,
17	and	and		@CC %CC CC
18	cycle	cycle	attr:&gt;19	@A&gt; %&gt;N N NOM SG
19	sequencing	sequencing		@NH %NH N NOM SG	@SUBJ %NH N NOM SG	@OBJ %NH N NOM SG	@APP %NH N 

NOM SG	@&lt;P %NH N NOM SG
20	,	,
21	alter	alter		@+FMAINV %VA V IMP
22	highly	highly	ad:&gt;23	@AD-A&gt; %E&gt; ADV
23	conserved	conserved	attr:&gt;24	@A&gt; %&gt;N A ABS
24	sequences	sequence	obj:&gt;21	@OBJ %NH N NOM PL
25	at	at	loc:&gt;21	@ADVL %EH PREP
26	intron/exon	intron-#exon	attr:&gt;27	@A&gt; %&gt;N N NOM SG
27	boundaries	boundary	pcomp:&gt;25	@&lt;P %NH N NOM PL
28	and	and	cc:&gt;21	@CC %CC CC
29	prevent	prevent	cc:&gt;21	@+FMAINV %VA V IMP
30	the	the	det:&gt;32	@DN&gt; %&gt;N DET
31	RNA-splicing	rna-splicing	attr:&gt;32	@A&gt; %&gt;N N NOM SG
32	apparatus	apparatus	obj:&gt;29	@OBJ %NH N NOM SG
33	from	from	phr:&gt;29	@ADVL %EH PREP
34	properly	properly		@ADVL %EH ADV	@AD-A&gt; %E&gt; ADV
35	recognizing	recognize	pcomp:&gt;33	@&lt;P-FMAINV %VA ING
36	the	the	det:&gt;39	@DN&gt; %&gt;N DET
37	normal	normal	attr:&gt;38	@A&gt; %&gt;N A ABS
38	splice	splice	attr:&gt;39	@A&gt; %&gt;N N NOM SG
39	junction	junction	obj:&gt;35	@OBJ %NH N NOM SG
40	.     .
</fdg>
</example>
<example src="MEDLINE" no="3">
<text>
A number of Ags recognized by class I-restricted melanoma-specific T cells have recently been isolated, raising the hope that this will lead to the development of improved therapies.

</text>
       <arg n="0">class I-restricted melanoma-specific T cells
</arg>
       <arg n="1">A number of Ags
</arg>
<fdg>

1	A	a	det:&gt;2	@DN&gt; %&gt;N DET SG
2	number	number	subj:&gt;12	@SUBJ %NH N NOM
3	of	of	mod:&gt;2	@&lt;NOM-OF %N&lt; PREP
4	Ags	ags	pcomp:&gt;3	@&lt;P %NH &lt;?&gt; N NOM SG
5	recognized	recognize	mod:&gt;4	@-FMAINV %VP EN
6	by	by	ha:&gt;5	@ADVL %EH PREP
7	class	class	attr:&gt;8	@A&gt; %&gt;N N NOM
8	I-restricted	i-restricted	pcomp:&gt;6	@&lt;P %NH N NOM SG
9	melanoma-specific	melanoma-specific	attr:&gt;10	@A&gt; %&gt;N A ABS
10	T	t	attr:&gt;11	@A&gt; %&gt;N ABBR NOM SG
11	cells	cell	obj:&gt;5	@OBJ %NH N NOM PL
12	have	have	v-ch:&gt;14	@+FAUXV %AUX V PRES
13	recently	recently	tmp:&gt;15	@ADVL %EH ADV
14	been	be	v-ch:&gt;15	@-FAUXV %AUX EN
15	isolated	isolate	main:&gt;0	@-FMAINV %VP EN
16	,	,
17	raising	raise	man:&gt;15	@-FMAINV %VA ING
18	the	the	det:&gt;19	@DN&gt; %&gt;N DET
19	hope	hope	obj:&gt;17	@OBJ %NH N NOM SG
20	that	that	pm:&gt;23	@CS %CS CS
21	this	this	subj:&gt;22	@SUBJ %NH PRON DEM SG
22	will	will	v-ch:&gt;23	@+FAUXV %AUX V AUXMOD
23	lead	lead	mod:&gt;19	@-FMAINV %VA V INF
24	to	to	ha:&gt;23	@ADVL %EH PREP
25	the	the	det:&gt;26	@DN&gt; %&gt;N DET
26	development	development	pcomp:&gt;24	@&lt;P %NH N NOM SG
27	of	of	mod:&gt;26	@&lt;NOM-OF %N&lt; PREP
28	improved	improved	attr:&gt;29	@A&gt; %&gt;N A ABS
29	therapies	therapy	pcomp:&gt;27	@&lt;P %NH N NOM PL
30	.     .
</fdg>
</example>
<example src="MEDLINE" no="4">
<text>
Exactly how specific splice sites are recognized during the processing of complex precursor messenger RNAs is not clear.

</text>
       <arg n="0">-
</arg>
       <arg n="1">splice sites
</arg>
<fdg>
1	Exactly	exactly	meta:&gt;7	@ADVL %EH ADV
2	how	how	man:&gt;7	@ADVL %EH ADV WH
3	specific	specific	attr:&gt;4	@A&gt; %&gt;N A ABS
4	splice	splice	attr:&gt;5	@A&gt; %&gt;N N NOM SG
5	sites	site	subj:&gt;6	@SUBJ %NH N NOM PL
6	are	be	v-ch:&gt;7	@+FAUXV %AUX V PRES
7	recognized	recognize	subj:&gt;16	@-FMAINV %VP EN
8	during	during	ha:&gt;7	@ADVL %EH PREP
9	the	the	det:&gt;10	@DN&gt; %&gt;N DET
10	processing	processing	pcomp:&gt;8	@&lt;P %NH N NOM SG
11	of	of	mod:&gt;10	@&lt;NOM-OF %N&lt; PREP
12	complex	complex	attr:&gt;13	@A&gt; %&gt;N A ABS
13	precursor	precursor	attr:&gt;14	@A&gt; %&gt;N N NOM SG
14	messenger	messenger	attr:&gt;15	@A&gt; %&gt;N N NOM SG
15	RNAs	rnas	pcomp:&gt;11	@&lt;P %NH N NOM SG
16	is	be	main:&gt;0	@+FMAINV %VA V PRES SG3
17	not	not	neg:&gt;16	@ADVL %EH NEG-PART
18	clear	clear	comp:&gt;16	@PCOMPL-S %NH A ABS
19	.     .
</fdg>
</example>
<example src="MEDLINE" no="5">
<text>
Anti-64kD human autoantigen D1 antibodies recognize specifically a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle.

</text>
       <arg n="0">Anti-64kD human autoantigen D1 antibodies
</arg>
       <arg n="1">a approximately 70kD polypeptide in western blots of extraocular muscle, sternothyroid muscle, and smooth muscle 
</arg>
<fdg>

1	Anti-64kD	anti-64kd	attr:&gt;2	@A&gt; %&gt;N &lt;?&gt; N NOM SG
2	human	human	attr:&gt;3	@A&gt; %&gt;N A ABS
3	autoantigen	autoantigen	attr:&gt;4	@A&gt; %&gt;N &lt;?&gt; N NOM SG
4	D1	d1	attr:&gt;5	@A&gt; %&gt;N N NOM SG
5	antibodies	antibody	subj:&gt;6	@SUBJ %NH N NOM PL
6	recognize	recognize	main:&gt;0	@+FMAINV %VA V PRES
7	specifically	specifically	man:&gt;6	@ADVL %EH ADV
8	a	a	det:&gt;11	@DN&gt; %&gt;N DET SG
9	approximately	approximately	ad:&gt;10	@AD-A&gt; %E&gt; ADV
10	70kD	70kd	attr:&gt;11	@A&gt; %&gt;N N NOM SG
11	polypeptide	polypeptide	obj:&gt;6	@OBJ %NH N NOM SG
12	in	in	ha:&gt;6	@ADVL %EH PREP
13	western	western	attr:&gt;14	@A&gt; %&gt;N A ABS
14	blots	blot	pcomp:&gt;12	@&lt;P %NH N NOM PL
15	of	of	mod:&gt;14	@&lt;NOM-OF %N&lt; PREP
16	extraocular	extraocular	attr:&gt;17	@A&gt; %&gt;N &lt;?&gt; A ABS
17	muscle	muscle	pcomp:&gt;15	@&lt;P %NH N NOM SG
18	,	,
19	sternothyroid	sternothyroid	attr:&gt;20	@A&gt; %&gt;N &lt;?&gt; N NOM SG
20	muscle	muscle	cc:&gt;17	@&lt;P %NH N NOM SG
21	,	,
22	and	and	cc:&gt;20	@CC %CC CC
23	smooth	smooth	attr:&gt;24	@A&gt; %&gt;N A ABS
24	muscle	muscle	cc:&gt;20	@&lt;P %NH N NOM SG
25	.     .
</fdg>
</example>
<example src="MEDLINE" no="6">
<text>
These bands can be detected with four different specific antibodies recognizing the different nonmuscle myosin heavy chain isoforms (A and B)

</text>
       <arg n="0">four different specific antibodies</arg>
	   <arg n="1">the different nonmuscle myosin heavy chain isoforms (A and B)</arg>

<fdg>
      

1	These	this	det:&gt;2	@DN&gt; %&gt;N DET DEM PL
2	bands	band	subj:&gt;3	@SUBJ %NH N NOM PL
3	can	can	v-ch:&gt;4	@+FAUXV %AUX V AUXMOD
4	be	be	v-ch:&gt;5	@-FAUXV %AUX V INF
5	detected	detect	main:&gt;0	@-FMAINV %VP EN
6	with	with	ha:&gt;5	@ADVL %EH PREP
7	four	four	qn:&gt;10	@QN&gt; %&gt;N NUM CARD
8	different	different	attr:&gt;9	@A&gt; %&gt;N A ABS
9	specific	specific	attr:&gt;10	@A&gt; %&gt;N A ABS
10	antibodies	antibody	pcomp:&gt;6	@&lt;P %NH N NOM PL
11	recognizing	recognize	mod:&gt;10	@-FMAINV %VA ING
12	the	the	det:&gt;20	@DN&gt; %&gt;N DET
13	two	two	qn:&gt;20	@QN&gt; %&gt;N NUM CARD
14	different	different	attr:&gt;15	@A&gt; %&gt;N A ABS
15	smooth	smooth	attr:&gt;16	@A&gt; %&gt;N A ABS
16	muscle	muscle	attr:&gt;17	@A&gt; %&gt;N N NOM SG
17	myosin	myosin	attr:&gt;18	@A&gt; %&gt;N N NOM SG
18	heavy	heavy	attr:&gt;19	@A&gt; %&gt;N A ABS
19	chain	chain	attr:&gt;20	@A&gt; %&gt;N N NOM SG
20	isoforms	isoform	obj:&gt;11	@OBJ %NH &lt;?&gt; N NOM PL
21	(	(
22	204	204		@QN&gt; %&gt;N NUM CARD
23	kDa	kda	mod:&gt;20	@APP %NH &lt;?&gt; N NOM SG
24	and	and		@CC %CC CC
25	200	200		@QN&gt; %&gt;N NUM CARD
26	kDa	kda		@NH %NH &lt;?&gt; N NOM SG	@SUBJ %NH &lt;?&gt; N NOM SG	@APP %NH &lt;?&gt; N NOM SG	@A&gt; %&gt;N &lt;?&gt; N 

NOM SG
27	)	)
28	and	and	cc:&gt;20	@CC %CC CC
29	the	the	det:&gt;36	@DN&gt; %&gt;N DET
30	two	two	qn:&gt;36	@QN&gt; %&gt;N NUM CARD
31	different	different	attr:&gt;32	@A&gt; %&gt;N A ABS
32	nonmuscle	nonmuscle	attr:&gt;33	@A&gt; %&gt;N &lt;?&gt; N NOM SG
33	myosin	myosin	attr:&gt;34	@A&gt; %&gt;N N NOM SG
34	heavy	heavy	attr:&gt;35	@A&gt; %&gt;N A ABS
35	chain	chain	attr:&gt;36	@A&gt; %&gt;N N NOM SG
36	isoforms	isoform	cc:&gt;20	@OBJ %NH &lt;?&gt; N NOM PL
37	(	(
38	A	a		@NH %NH ABBR NOM SG
39	and	and	cc:&gt;38	@CC %CC CC
40	B	b	cc:&gt;38	@NH %NH ABBR NOM SG
41	)	)
42	.     .
</fdg>
</example>
<example src="MEDLINE" no="7">
<text>
To define the subcellular location of HVDAC isoforms, HVDAC genes were modified so that the encoded proteins contain COOH-terminal epitopes recognized by either of two monoclonal antibodies. 

</text>
       <arg n="0">either of two monoclonal antibodies
</arg>
       <arg n="1">COOH-terminal epitopes
</arg>
<fdg>

1	To	to	pm:&gt;2	@INFMARK&gt; %AUX INFMARK&gt;
2	define	define	cnt:&gt;13	@-FMAINV %VA V INF
3	the	the	det:&gt;5	@DN&gt; %&gt;N DET
4	subcellular	subcellular	attr:&gt;5	@A&gt; %&gt;N A ABS
5	location	location	obj:&gt;2	@OBJ %NH N NOM SG
6	of	of	mod:&gt;5	@&lt;NOM-OF %N&lt; PREP
7	HVDAC	hvdac	attr:&gt;8	@A&gt; %&gt;N N NOM SG
8	isoforms	isoform	pcomp:&gt;6	@&lt;P %NH &lt;?&gt; N NOM PL
9	,	,
10	HVDAC	hvdac	attr:&gt;11	@A&gt; %&gt;N N NOM SG
11	genes	gene	subj:&gt;12	@SUBJ %NH N NOM PL
12	were	be	v-ch:&gt;13	@+FAUXV %AUX V PAST PL
13	modified	modify	main:&gt;0	@-FMAINV %VP EN
14	so	so	pm:&gt;15	@ADVL %EH ADV
15	that	that	pm:&gt;19	@CS %CS CS
16	the	the	det:&gt;18	@DN&gt; %&gt;N DET
17	encoded	encoded	attr:&gt;18	@A&gt; %&gt;N A ABS
18	proteins	protein	subj:&gt;19	@SUBJ %NH N NOM PL
19	contain	contain	obj:&gt;13	@+FMAINV %VA V PRES
20	COOH-terminal	cooh-terminal	attr:&gt;21	@A&gt; %&gt;N N NOM SG
21	epitopes	epitop*	obj:&gt;19	@OBJ %NH &lt;?&gt; N NOM
22	recognized	recognize	mod:&gt;21	@-FMAINV %VP EN
23	by	by	ha:&gt;22	@ADVL %EH PREP
24	either	either	pcomp:&gt;23	@&lt;P %NH PRON NOM SG
25	of	of	mod:&gt;24	@&lt;NOM-OF %N&lt; PREP
26	two	two	qn:&gt;28	@QN&gt; %&gt;N NUM CARD
27	monoclonal	monoclonal	attr:&gt;28	@A&gt; %&gt;N A ABS
28	antibodies	antibody	pcomp:&gt;25	@&lt;P %NH N NOM PL
29	.     .
</fdg>
</example>
<example src="EMBO" no="1">
<text>
Individual cell clones were analyzed for STAT1 expression by immunofluorescence with a monoclonal antibody recognizing the STAT1 N-terminus, and by western blotting.

</text>
       <arg n="0">a monoclonal antibody
</arg>
       <arg n="1">the STAT1 N-terminus
</arg>
<fdg>
1	Individual	individual	attr:&gt;2	@A&gt; %&gt;N A ABS
2	cell	cell	attr:&gt;3	@A&gt; %&gt;N N NOM SG
3	clones	clone	subj:&gt;4	@SUBJ %NH N NOM PL
4	were	be	v-ch:&gt;5	@+FAUXV %AUX V PAST PL
5	analyzed	analyze	main:&gt;0	@-FMAINV %VP EN
6	for	for	ha:&gt;5	@ADVL %EH PREP
7	STAT1	stat1	attr:&gt;8	@A&gt; %&gt;N N NOM SG
8	expression	expression	pcomp:&gt;6	@&lt;P %NH N NOM SG
9	by	by	agt:&gt;5	@ADVL %EH PREP
10	immunofluorescence	immunofluorescence	pcomp:&gt;9	@&lt;P %NH &lt;?&gt; N NOM SG
11	with	with		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
12	a	a	det:&gt;14	@DN&gt; %&gt;N DET SG
13	monoclonal	monoclonal	attr:&gt;14	@A&gt; %&gt;N A ABS
14	antibody	antibody	pcomp:&gt;11	@&lt;P %NH N NOM SG
15	recognizing	recognize	mod:&gt;14	@-FMAINV %VA ING
16	the	the	det:&gt;18	@DN&gt; %&gt;N DET
17	STAT1	stat1	attr:&gt;18	@A&gt; %&gt;N N NOM SG
18	N-terminus	n-terminus	obj:&gt;15	@OBJ %NH N NOM SG
19	,	,
20	and	and	cc:&gt;14	@CC %CC CC
21	by	by		@ADVL %EH PREP
22	western	western	cc:&gt;14	@&lt;P %NH A ABS
23	blotting	blotting	pcomp:&gt;21	@&lt;P %NH N NOM SG
24	.     .
</fdg>
</example>
<example src="EMBO" no="2">
<text>
A monoclonal antibody recognizing the STAT1 N-terminus was purchased from Transduction Laboratories (Lexington, KY).

</text>
       <arg n="0">A monoclonal antibody
</arg>
       <arg n="1">the STAT1 N-terminus
</arg>
<fdg>
1	A	a	det:&gt;3	@DN&gt; %&gt;N DET SG
2	monoclonal	monoclonal	attr:&gt;3	@A&gt; %&gt;N A ABS
3	antibody	antibody	subj:&gt;8	@SUBJ %NH N NOM SG
4	recognizing	recognize	mod:&gt;3	@-FMAINV %VA ING
5	the	the	det:&gt;7	@DN&gt; %&gt;N DET
6	STAT1	stat1	attr:&gt;7	@A&gt; %&gt;N N NOM SG
7	N-terminus	n-terminus	obj:&gt;4	@OBJ %NH N NOM SG
8	was	be	v-ch:&gt;9	@+FAUXV %AUX V PAST
9	purchased	purchase	main:&gt;0	@-FMAINV %VP EN
10	from	from	sou:&gt;9	@ADVL %EH PREP
11	Transduction	transduction	attr:&gt;12	@A&gt; %&gt;N N NOM SG
12	Laboratories	laboratory	pcomp:&gt;10	@&lt;P %NH N NOM PL
13	(	(
14	Lexington	lexington	mod:&gt;12	@NH %NH N NOM SG
15	,	,
16	KY	ky	mod:&gt;14	@APP %NH ABBR NOM SG
17	)	)
18	.     .
</fdg>
</example>
<example src="EMBO" no="3">
<text>
The two forms of Stat3 (Stat3fm and Stat3sm) recognized by this antibody in PKR+/+MEFs are indicated.

</text>
       <arg n="0">this antibody in PKR+/+MEFs
</arg>
       <arg n="1">The two forms of Stat3 (Stat3fm and Stat3sm)
</arg>
<fdg>
1	The	the	det:&gt;3	@DN&gt; %&gt;N DET
2	two	two	qn:&gt;3	@QN&gt; %&gt;N NUM CARD
3	forms	form		@NH %NH N NOM PL	@PCOMPL-S %NH N NOM PL
4	of	of	mod:&gt;3	@&lt;NOM-OF %N&lt; PREP
5	Stat3	stat3	pcomp:&gt;4	@&lt;P %NH N NOM SG
6	(	(
7	Stat3fm	stat3fm	mod:&gt;5	@NH %NH &lt;?&gt; N NOM SG
8	and	and	cc:&gt;7	@CC %CC CC
9	Stat3sm	stat3sm	cc:&gt;7	@NH %NH &lt;?&gt; N NOM SG
10	)	)
11	recognized	recognize		@-FMAINV %VP EN
12	by	by	ha:&gt;11	@ADVL %EH PREP
13	this	this	det:&gt;14	@DN&gt; %&gt;N DET DEM SG
14	antibody	antibody	pcomp:&gt;12	@&lt;P %NH N NOM SG
15	in	in	mod:&gt;14	@&lt;NOM %N&lt; PREP
16	PKR	pkr	pcomp:&gt;15	@&lt;P %NH N NOM SG
17	+	+		@CC %CC CC
18	/	/	
19	+	+		@CC %CC CC
20	MEFs	mefs		@SUBJ %NH N NOM SG	@PCOMPL-S %NH N NOM SG	@APP %NH N NOM SG	@&lt;P %NH N NOM SG
21	are	be	v-ch:&gt;22	@+FAUXV %AUX V PRES
22	indicated	indicate		@-FMAINV %VP EN
23	.     .
</fdg>
</example>
<example src="EMBO" no="4">
<text>
The lower form of Stat3, Stat3Beta, is not recognized in the immunoprecipitaiton with anti-Stat3 pAb as it is raised against a C-terminal region of Stat3 that is missing in Stat3Beta.

</text>
       <arg n="0">anti-Stat3 pAb 
</arg>
       <arg n="1">The lower form of Stat3, Stat3Beta
</arg>
       <arg n="M-NEG">not
</arg>
<fdg>

1	The	the	det:&gt;3	@DN&gt; %&gt;N DET
2	lower	low	attr:&gt;3	@A&gt; %&gt;N A CMP
3	form	form	subj:&gt;9	@SUBJ %NH N NOM SG
4	of	of	mod:&gt;3	@&lt;NOM-OF %N&lt; PREP
5	Stat3	stat3	pcomp:&gt;4	@&lt;P %NH N NOM SG
6	,	,
7	Stat3ß	stat3ß	mod:&gt;5	@APP %NH &lt;?&gt; N NOM SG
8	,	,
9	is	be	v-ch:&gt;11	@+FAUXV %AUX V PRES SG3
10	not	not	neg:&gt;9	@ADVL %EH NEG-PART
11	recognized	recognize	main:&gt;0	@-FMAINV %VP EN
12	in	in	ha:&gt;11	@ADVL %EH PREP
13	the	the	det:&gt;14	@DN&gt; %&gt;N DET
14	immunoprecipitation	immunoprecipitation	pcomp:&gt;12	@&lt;P %NH &lt;?&gt; N NOM SG
15	with	with		@&lt;NOM %N&lt; PREP	@ADVL %EH PREP
16	anti-Stat3	anti-stat3		@QN&gt; %&gt;N &lt;?&gt; NUM CARD
17	pAb	pab	pcomp:&gt;15	@&lt;P %NH &lt;?&gt; N NOM SG
18	as	as	pm:&gt;21	@CS %CS CS
19	it	it	subj:&gt;20	@SUBJ %NH PRON NOM SG3
20	is	be	v-ch:&gt;21	@+FAUXV %AUX V PRES SG3
21	raised	raise	man:&gt;11	@-FMAINV %VP EN
22	against	against	ha:&gt;21	@ADVL %EH PREP
23	a	a	det:&gt;25	@DN&gt; %&gt;N DET SG
24	C-terminal	c-terminal	attr:&gt;25	@A&gt; %&gt;N A ABS
25	region	region	pcomp:&gt;22	@&lt;P %NH N NOM SG
26	of	of	mod:&gt;25	@&lt;NOM-OF %N&lt; PREP
27	Stat3	stat3	pcomp:&gt;26	@&lt;P %NH N NOM SG
28	that	that	subj:&gt;29	@SUBJ %NH &lt;Rel&gt; PRON
29	is	be	v-ch:&gt;30	@+FAUXV %AUX V PRES SG3
30	missing	miss	mod:&gt;27	@-FMAINV %VA ING
31	in	in	loc:&gt;30	@ADVL %EH PREP
32	Stat3ß	stat3ß	pcomp:&gt;31	@&lt;P %NH &lt;?&gt; N NOM SG
33	.     .
</fdg>
</example>
  
<example src="EMBO" no="5">
  <text>
    Blots were probed with affinity-purified polyclonal anti-LMP-1 antiserum that recognizes epitopes in the C-terminus of LMP-1 at a 1:200 dilution.

  </text>
  <arg n="0">
    affinity-purified polyclonal anti-LMP-1 antiserum
  </arg>
  <arg n="1">
    epitopes in the C-terminus of LMP-1 at a 1:200 dilution
  </arg>
</example>

<example src="EMBO" no="6">
  <text>
    Blots were probed with a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim) that recognizes the sequence(YPYDVPDYA) at a 1:500 dilution.
  </text>
  <arg n="0">
    a RAT monoclonal anti-HA antibody (Boehringer-Ingelheim)
  </arg>
  <arg n="1">
    sequence(YPYDVPDYA) at a 1:500 dilution
  </arg>
</example>

<example src="EMBO" no="7">
  <text>
    Blots were probed with rabbit polyclonal anti-CD40 antiserum that recognizes the C-terminus of CD40 at a 1:500 dilution, or with rabbit polyclonal anti-GFP or anti-RFP (Clontech) antiserum at a 1:250 dilution.

  </text>
  <arg n="0">
    rabbit polyclonal anti-CD40 antiserum
  </arg>
  <arg n="1">
    C-terminus of CD40 at a 1:500 dilution
  </arg>
</example>
</roleset>
</predicate>
</frameset>
